Powered by

Achillion Announces First Dosing in Phase 1 Multiple Ascending Dose Study of ACH-5228 Next-Generation Oral Factor D Inhibitor in Healthy Volunteers

Jan 31, 2019 - GlobeNewswire

- ACH-5228, with improved potency and half-life, increases alternative pathway inhibition -- Achillion planning Investigational New Drug (IND) submission in fourth quarter of 2019 -

NEW HAVEN, Conn., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced dosing of the first healthy volunteer in a Phase...